RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals ...

Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...

In March 2024, Fennec entered into an exclusive licensing ... PEDMARK is also recommended for the Adolescent and Young Adult (AYA) population by the National Comprehensive Cancer Network® as ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

Rosty Raykov, a director at Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a company currently valued at $187 million, has sold 10,000 common shares of the company, according to a recent SEC filing.

If you’re curious as to how and why cows, nuclear reactors, tricycles, peperami, and old people doing yoga all fit into one ...

RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today ...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of ...